Konakanchi Venkata Chalam, Kar Bikash R, Sathishkumar Dharshini, Tahiliani Sushil, Parthasarathi Anchala, Neema Shekhar, Ganguly Satyaki, Parasramani Shrichand G, Komeravelli Haritha, Thomas Jayakar
From the Department of DVL, RIMS, Srikakulam, Andhra Pradesh, India.
Department of DVL, IMS and SUM Hospital, Bhubaneswar, Odisha, India.
Indian J Dermatol. 2024 May-Jun;69(3):249-255. doi: 10.4103/ijd.ijd_166_24. Epub 2024 Jun 26.
Psoriasis is a common chronic, immune-mediated inflammatory skin disease associated with various comorbidities. Managing psoriasis is often challenging as the therapy is decided based on the area of the disease, associated comorbidities and impairment in quality of life, besides the patient's preference. Making progress in the development of new molecules that can be used topically or orally, effectively controlling the disease with minimal side effects and providing long-lasting remissions are the needs of the hour. Recent developments in understanding the complexities of the pathogenesis of psoriasis have resulted in the reinforcement of treatment modalities, leading to the evolution of various biologics and small-molecule inhibitors. In comparison with biologics, both patients and treating physicians prefer small molecules for various reasons such as avoiding injections and side effects that are associated with biologics biologics. Moreover small molecules are economical than biologics. Newer small molecules, both topical and oral, are promising additions to the therapeutic arsenal in the management of psoriasis in the future.
银屑病是一种常见的慢性、免疫介导的炎症性皮肤病，与多种合并症相关。银屑病的治疗往往具有挑战性，因为除了患者的偏好外，治疗方案还需根据疾病面积、相关合并症以及生活质量受损情况来决定。开发可局部或口服使用的新分子，以最小的副作用有效控制疾病并实现长期缓解，是当下的迫切需求。近年来，对银屑病发病机制复杂性的深入理解促使治疗方式不断强化，推动了各种生物制剂和小分子抑制剂的发展。与生物制剂相比，患者和治疗医生因各种原因更倾向于小分子药物，如避免注射以及生物制剂相关的副作用。此外，小分子药物比生物制剂更经济。新型小分子药物，包括局部和口服的，有望在未来成为银屑病治疗手段中的有力补充。
